Featured Research

from universities, journals, and other organizations

Empty decoys divert antibodies from neutralizing gene therapy in cell, animal studies

Date:
July 17, 2013
Source:
Children's Hospital of Philadelphia
Summary:
Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene. The decoy was effective in animal studies, and if the approach succeeds in humans, it offers a potential new treatment for genetic diseases such as hemophilia, while advancing the broader field of gene therapy.

Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene. The decoy was effective in animal studies, and if the approach succeeds in humans, it offers a potential new treatment for genetic diseases such as hemophilia, while advancing the broader field of gene therapy.

Related Articles


"This decoy strategy could be individualized to patients and could greatly expand the population of patients who may benefit from gene therapy," said study leader Katherine A. High, M.D., director of the Center for Cellular and Molecular Therapeutics (CCMT) at The Children's Hospital of Philadelphia. "Right now, 30 to 60 percent of adult patients develop antibodies that block the ability of an intravenously infused vector to reach the target cells in the liver. This approach holds the promise of overcoming this roadblock -- pre-existing antibodies -- and allowing successful intravenous gene therapy in virtually all adult patients."

High and co-corresponding author Federico Mingozzi, Ph.D., formerly of Children's Hospital, published the team's study today in Science Translational Medicine.

High, a Howard Hughes Medical Institute Investigator, has led pioneering investigations of gene therapy at Children's Hospital for the inherited bleeding disorder hemophilia and other diseases.

Previously, in clinical trials, High used adeno-associated virus (AAV) as a vector -- a delivery vehicle -- to ferry a corrective DNA sequence to patients with a mutation causing hemophilia B, the second most common form of the disease. The delivered gene enables the patient to produce a needed blood-clotting factor.

AAV does not cause human disease, but because we are routinely exposed to this virus, 30 to 60 percent of people develop antibodies that neutralize AAV if it enters the circulation. To extend the potential benefits of gene therapy to a broader population, researchers have long sought ways to better manage this immune response. The decoy strategy could solve this challenge for any disease in which vectors must be delivered through the circulation.

The current study by High and colleagues relies on a capsid, the protein shell surrounding a virus. Following in vitro studies in human serum, the researchers injected empty AAV capsids along with gene therapy vectors into a mouse model. The anti-AAV neutralizing antibodies bound to the capsid decoys, allowing the DNA-carrying vectors to evade the antibodies and enter the targeted cells in the liver.

The study team next engineered the capsids to disable their ability to enter target cells. This prevented the capsids from triggering a second immune response, from T cells, that also could eliminate the corrective genes. The gene therapy was safe and effective in rhesus macaque monkeys, which produced higher levels of clotting factor, with no adverse effects.

"Our results, which held up over a range of doses, suggest that in clinical studies, it will be feasible to adjust the ratio of empty capsids to gene vector doses, depending on an individual's pre-existing level of neutralizing antibodies," said High. "That means we could personalize gene therapy to make it more efficient for each patient."

"This work should make it possible to bring effective gene therapy to most adults with severe hemophilia B," High continued. "Each patient would receive a personalized final formulation that contains just the right amount of empty capsid to neutralize any pre-existing antibody, and allow the gene-expressing vector to reach the liver."

Support for this study came from the National Institutes of Health (grant HL078810) and the Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia. The Howard Hughes Medical Institute (HHMI) also provided support.

High's and Mingozzi's co-authors were from Children's Hospital and the Perelman School of Medicine at the University of Pennsylvania (where High is a faculty member). Another co-author was Xavier M. Anguela, Ph.D., of both the CCMT and HHMI.


Story Source:

The above story is based on materials provided by Children's Hospital of Philadelphia. Note: Materials may be edited for content and length.


Journal Reference:

  1. Federico Mingozzi, Xavier M. Anguela, Giulia Pavani, Yifeng Chen, Robert J. Davidson, Daniel J. Hui, Mustafa Yazicioglu, Liron Elkouby, Christian J. Hinderer, Armida Faella, Carolann Howard, Alex Tai, Gregory M. Podsakoff, Shangzhen Zhou, Etiena Basner-Tschakarjan, John Fraser Wright, Katherine A. High. Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. Science Translational Medicine, 2013; 5 (194): 194ra92 DOI: 10.1126/scitranslmed.3005795

Cite This Page:

Children's Hospital of Philadelphia. "Empty decoys divert antibodies from neutralizing gene therapy in cell, animal studies." ScienceDaily. ScienceDaily, 17 July 2013. <www.sciencedaily.com/releases/2013/07/130717141736.htm>.
Children's Hospital of Philadelphia. (2013, July 17). Empty decoys divert antibodies from neutralizing gene therapy in cell, animal studies. ScienceDaily. Retrieved March 4, 2015 from www.sciencedaily.com/releases/2013/07/130717141736.htm
Children's Hospital of Philadelphia. "Empty decoys divert antibodies from neutralizing gene therapy in cell, animal studies." ScienceDaily. www.sciencedaily.com/releases/2013/07/130717141736.htm (accessed March 4, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, March 4, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mom Triumphs Over Tragedy, Helps Other Families

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3) Video provided by AP
Powered by NewsLook.com
Looted and Leaking, South Sudan's Oil Wells Pose Health Risk

Looted and Leaking, South Sudan's Oil Wells Pose Health Risk

AFP (Mar. 3, 2015) Thick black puddles and a looted, leaking ruin are all that remain of the Thar Jath oil treatment facility, once a crucial part of South Sudan&apos;s mainstay industry. Duration: 01:13 Video provided by AFP
Powered by NewsLook.com
Woman Convicted of Poisoning Son

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3) Video provided by AP
Powered by NewsLook.com
Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins